The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) is a partnership between three world-renowned academic institutions — Memorial Sloan Kettering, The Rockefeller University and Weill Cornell Medical College — with a mission to speed the translation of basic science discoveries into the clinic. Launched in 2013, the Tri-I TDI focuses on the early stages of developing compounds and biologic agents through “proof-of-concept” studies, which aim to demonstrate that a drug candidate can successfully alter the course of a disease.
The Tri-I TDI brings together the complementary strengths and resources of its member institutions and provides additional expertise in medicinal chemistry and compound screening through its partnership with Takeda Pharmaceutical Company.
The institute supports the development of new drugs for cancers and many other conditions including infectious diseases, cardiovascular and metabolic disorders, inflammatory diseases, and neurodegenerative disorders.
